Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:BBIO NASDAQ:ERAS NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$218.84+0.9%$233.36$160.86▼$250.74$13.52B0.39578,926 shs467,681 shsBBIOBridgeBio Pharma$67.33+2.8%$70.78$37.69▼$84.94$12.82B0.973.06 million shs1.97 million shsERASErasca$13.27+0.7%$14.50$1.21▼$24.28$4.10B0.734.40 million shs7.96 million shsSMMTSummit Therapeutics$14.84-1.5%$19.02$13.83▼$30.98$11.70B-1.324.75 million shs5.36 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+0.95%-7.85%-2.86%-9.06%+25.99%BBIOBridgeBio Pharma+2.83%-1.64%-2.11%+3.01%+77.09%ERASErasca+0.68%+8.77%+32.83%-14.22%+767.32%SMMTSummit Therapeutics-1.53%-14.76%-15.39%-1.79%-24.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$218.84+0.9%$233.36$160.86▼$250.74$13.52B0.39578,926 shs467,681 shsBBIOBridgeBio Pharma$67.33+2.8%$70.78$37.69▼$84.94$12.82B0.973.06 million shs1.97 million shsERASErasca$13.27+0.7%$14.50$1.21▼$24.28$4.10B0.734.40 million shs7.96 million shsSMMTSummit Therapeutics$14.84-1.5%$19.02$13.83▼$30.98$11.70B-1.324.75 million shs5.36 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+0.95%-7.85%-2.86%-9.06%+25.99%BBIOBridgeBio Pharma+2.83%-1.64%-2.11%+3.01%+77.09%ERASErasca+0.68%+8.77%+32.83%-14.22%+767.32%SMMTSummit Therapeutics-1.53%-14.76%-15.39%-1.79%-24.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$295.3934.98% UpsideBBIOBridgeBio Pharma 2.85Moderate Buy$89.5933.06% UpsideERASErasca 2.60Moderate Buy$20.1151.55% UpsideSMMTSummit Therapeutics 2.39Hold$26.0575.57% UpsideCurrent Analyst Ratings BreakdownLatest ERAS, ASND, SMMT, and BBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026ERASErasca Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$16.006/4/2026ERASErasca Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderperform ➝ Neutral$9.00 ➝ $16.006/3/2026BBIOBridgeBio Pharma Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$104.006/1/2026SMMTSummit Therapeutics KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/28/2026BBIOBridgeBio Pharma Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$94.00 ➝ $98.005/28/2026BBIOBridgeBio Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$110.005/26/2026BBIOBridgeBio Pharma Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/22/2026SMMTSummit Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/22/2026SMMTSummit Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/21/2026SMMTSummit Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageUnderperform$7.705/21/2026SMMTSummit Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$865.78M15.77N/AN/A($2.97) per share-73.68BBIOBridgeBio Pharma$579.96M22.74N/AN/A($10.77) per share-6.25ERASErascaN/AN/AN/AN/A$1.05 per shareN/ASMMTSummit TherapeuticsN/AN/AN/AN/A$0.85 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$258M$8.6725.2420.36N/A57.87%N/A-8.37%8/6/2026 (Estimated)BBIOBridgeBio Pharma-$724.93M-$3.74N/A292.74N/A-124.42%N/A-65.81%8/4/2026 (Estimated)ERASErasca-$124.55M-$0.93N/AN/AN/AN/A-35.31%-29.49%8/11/2026 (Estimated)SMMTSummit Therapeutics-$1.08B-$1.60N/AN/AN/AN/A-291.24%-243.07%8/10/2026 (Estimated)Latest ERAS, ASND, SMMT, and BBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026ERASErasca-$0.1150-$0.60-$0.4850-$0.60N/AN/A5/7/2026Q1 2026ASNDAscendis Pharma A/S$0.21$0.32+$0.11$11.29$362.47 million$285.45 million5/7/2026Q1 2026BBIOBridgeBio Pharma-$0.70-$0.84-$0.14-$0.84$178.07 million$194.52 million5/1/2026Q1 2026SMMTSummit Therapeutics-$0.2692-$0.24+$0.0292-$0.24$0.05 millionN/A3/12/2026Q4 2025ERASErasca-$0.11-$0.10+$0.01-$0.10N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/AERASErascaN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/S0.791.000.72BBIOBridgeBio PharmaN/A1.521.48ERASErascaN/A9.529.52SMMTSummit TherapeuticsN/A7.417.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ABBIOBridgeBio Pharma99.85%ERASErasca67.78%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%BBIOBridgeBio Pharma14.23%ERASErasca14.20%SMMTSummit Therapeutics83.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,18962.38 million37.43 millionOptionableBBIOBridgeBio Pharma400195.86 million167.99 millionOptionableERASErasca120310.98 million266.83 millionOptionableSMMTSummit Therapeutics110776.16 million128.07 millionOptionableERAS, ASND, SMMT, and BBIO HeadlinesRecent News About These CompaniesAnalysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Oculis Holding (OCS) and Cogent Biosciences (COGT)June 4 at 2:51 PM | theglobeandmail.comAssessing Summit Therapeutics (SMMT) Valuation After A Mixed Share Price And Long Term Return ProfileJune 4 at 2:51 PM | finance.yahoo.comAll You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to BuyJune 4 at 1:01 PM | zacks.comSummit Therapeutics Inc. (SMMT) Discusses Plenary Session Updates and Recent Clinical Data Following Major Oncology Congress - SlideshowJune 3 at 7:19 PM | seekingalpha.comCantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical DevelopmentsJune 2 at 7:30 AM | insidermonkey.comSummit Therapeutics (SMMT) Sheds 10.4%, This Analyst is PessimisticJune 2 at 1:31 AM | insidermonkey.comSummit Therapeutics Inc. (SMMT) Discusses Plenary Session Updates and Recent Clinical Data Following Major Oncology Congress TranscriptJune 1, 2026 | seekingalpha.comWall Street Analysts Think Summit Therapeutics (SMMT) Could Surge 67.1%: Read This Before Placing a BetJune 1, 2026 | zacks.comSummit rises after lung cancer drug trial shows 15% higher survival rate than rival'sJune 1, 2026 | reuters.comIvonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONMay 31, 2026 | gurufocus.comIvonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in ChinaMay 31, 2026 | businesswire.comA hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in ChinaMay 31, 2026 | cnbc.comSummit downgraded at H.C. Wainwright after Merck data for sac-TMTMay 23, 2026 | seekingalpha.comBernstein initiates coverage of Summit Therapeutics (SMMT) with underperform recommendationMay 23, 2026 | msn.comHere's Why You Should Add SMMT Stock to Your Portfolio NowMay 22, 2026 | zacks.comCancer Stocks That Are Advancing the Future of Oncology CareMay 18, 2026 | zacks.comSummit Therapeutics PLC $SMMT Stock Holdings Decreased by Vanguard Group Inc.May 11, 2026 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Upgraded at Wall Street ZenMay 10, 2026 | marketbeat.comQ2 EPS Estimate for Summit Therapeutics Boosted by AnalystMay 8, 2026 | marketbeat.comQ2 Earnings Forecast for SMMT Issued By HC WainwrightMay 7, 2026 | marketbeat.comSMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab SetbackMay 4, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeERAS, ASND, SMMT, and BBIO Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$218.84 +2.05 (+0.95%) Closing price 06/4/2026 04:00 PM EasternExtended Trading$218.82 -0.02 (-0.01%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.BridgeBio Pharma NASDAQ:BBIO$67.33 +1.85 (+2.83%) Closing price 06/4/2026 04:00 PM EasternExtended Trading$67.77 +0.44 (+0.65%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Erasca NASDAQ:ERAS$13.27 +0.09 (+0.68%) Closing price 06/4/2026 04:00 PM EasternExtended Trading$13.50 +0.23 (+1.70%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Summit Therapeutics NASDAQ:SMMT$14.84 -0.23 (-1.53%) Closing price 06/4/2026 04:00 PM EasternExtended Trading$14.96 +0.12 (+0.78%) As of 07:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand Medtronic Bottoms, Healthy Rebound Ahead From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker GitLab’s Price Recovery Gains Traction—Time to Get On Board? Ulta's Q1 Report Primes It for a Beauty of a Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
